Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 301

Sort by

Sort Order Select

Journal Articles

Insights into the etiology of Castleman disease

Frits van Rhee, David Fajgenbaum

Blood (2024) 143 (18): 1789–1790.

https://doi.org/10.1182/blood.2023023716

Published: 2024

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Blood (2023) 142 (Supplement 1): 545.

https://doi.org/10.1182/blood-2023-174875

Published: 2023

Journal Articles

A 5-Stage System for ASCT Multiple Myeloma

Wancheng Guo, David E. Mery, Eric Siegel, Fumou Sun, Yan Cheng, Visanu Wanchai, Cody Ashby, Clyde Bailey, Daisy V. Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2023-181117

Published: 2023

Journal Articles

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Samer Al Hadidi, Obada Ababneh, Carson W Ercanbrack, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Guido Tricot, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Maurizio Zangari, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2023-181034

Published: 2023

Journal Articles

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Sheila K. Pierson, Joshua D. Brandstadter, Frits van Rhee, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2023-183039

Published: 2023

Journal Articles

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions

Fumou Sun, Yan Cheng, Jin-Ran Chen, Visanu Wanchai, David E. Mery, Hongwei Xu, Dongzheng Gai, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, John D Shaughnessy, Jr, Guido Tricot, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 452.

https://doi.org/10.1182/blood-2023-181853

Published: 2023

Journal Articles

Single Nuclei Multiomics Analysis of Transcriptional and Chromatin Accessibility of Tumor Cells Uncovers Molecular Signatures and Regulatory Elements of Malignant Clonal Evolution in Multiple Myeloma

Visanu Wanchai, Hongwei Xu, Cody Ashby, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 87.

https://doi.org/10.1182/blood-2023-181279

Published: 2023

Journal Articles

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Carolina Schinke, Leo Rasche, Cody Ashby, Rudy van Hemert, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Clyde Bailey, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Frits van Rhee, Niels Weinhold

Blood (2023) 142 (Supplement 1): 882.

https://doi.org/10.1182/blood-2023-180896

Published: 2023

Journal Articles

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

Yan Cheng, Fumou Sun, Wancheng Guo, Hongwei Xu, Prasanth Viswanathan, Mark Manzano, Eric Siegel, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Marta Chesi, P. Leif Bergsagel, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 3309.

https://doi.org/10.1182/blood-2023-187001

Published: 2023

Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2023-180761

Published: 2023

Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Blood (2023) 142 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2023-181905

Published: 2023

Journal Articles

The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 758.

https://doi.org/10.1182/blood-2023-186697

Published: 2023

Journal Articles

Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems

Wancheng Guo, David E. Mery, Eric Siegel, Fumou Sun, Yan Cheng, Cody Ashby, Daisy V. Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 6573.

https://doi.org/10.1182/blood-2023-181254

Published: 2023

Journal Articles

Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Tanvi H. Patel, Ramya Bachu, Trilok Shrivastava, Jawad Alrawabdeh, Marah Alzubi, Jael Hastings, Harold Dean, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Guido Tricot, Fenghuang Zhan, John D Shaughnessy, Jr, Frits van Rhee, Samer Al Hadidi

Blood (2023) 142 (Supplement 1): 6764.

https://doi.org/10.1182/blood-2023-180964

Published: 2023

Journal Articles

The Use and Reporting of Cytogenetics in Phase III Multiple Myeloma Clinical Trials

Obada Ababneh, Faris Jamal Abu Za'nouneh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Jr., Fenghuang Zhan, Frits van Rhee, Samer Al Hadidi

Blood (2022) 140 (Supplement 1): 12532–12533.

https://doi.org/10.1182/blood-2022-158282

Published: 2022

Journal Articles

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Daisy Alapat, Adam Bagg, Mary Jo Lechowicz, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 9378–9379.

https://doi.org/10.1182/blood-2022-170360

Published: 2022

Journal Articles

Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis

Farah Mazahreh, Liyan Mazahreh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Jr., Fenghuang Zhan, Frits van Rhee, Samer Al Hadidi

Blood (2022) 140 (Supplement 1): 4378.

https://doi.org/10.1182/blood-2022-157858

Published: 2022

Journal Articles

A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance

Blood (2022) 140 (Supplement 1): 264–265.

https://doi.org/10.1182/blood-2022-163654

Published: 2022

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

Clinical Research Focused on Supportive Care in Multiple Myeloma: A Cross Sectional Analysis

Hadeel Al-Zawahreh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Fenghuang Zhan, John D Shaughnessy, Jr., Frits van Rhee, Samer Al Hadidi

Blood (2022) 140 (Supplement 1): 13240–13241.

https://doi.org/10.1182/blood-2022-159652

Published: 2022

NARROW

Insights into the etiology of Castleman disease

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

A 5-Stage System for ASCT Multiple Myeloma

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions

Single Nuclei Multiomics Analysis of Transcriptional and Chromatin Accessibility of Tumor Cells Uncovers Molecular Signatures and Regulatory Elements of Malignant Clonal Evolution in Multiple Myeloma

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T in Multiple Myeloma

Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems

Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

The Use and Reporting of Cytogenetics in Phase III Multiple Myeloma Clinical Trials

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis

A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Clinical Research Focused on Supportive Care in Multiple Myeloma: A Cross Sectional Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only